Thus, anti-angiogenic neutralization of VEGF by anti-VEGF agents is currently the first line therapy and may be beneficial in the treatment of vascular leakage, macular edema, and neovascular glaucoma [17,19,20]. This evidence concerns the gene VEGFA and neovascular glaucoma.